--- title: "REG - Fulcrum Metals PLC - Holding(s) in Company" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/274341893.md" description: "Fulcrum Metals PLC has notified a major holding change, with Ryan Mee acquiring 9.42% of voting rights, totaling 13,024,123 shares, as of January 23, 2026. This marks a decrease from the previous holding of 10.46%. The notification was submitted on January 30, 2026, in compliance with regulatory requirements." datetime: "2026-01-30T17:27:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274341893.md) - [en](https://longbridge.com/en/news/274341893.md) - [zh-HK](https://longbridge.com/zh-HK/news/274341893.md) --- > 支持的语言: [English](https://longbridge.com/en/news/274341893.md) | [繁體中文](https://longbridge.com/zh-HK/news/274341893.md) # REG - Fulcrum Metals PLC - Holding(s) in Company RNS Number : 1811R Fulcrum Metals PLC 30 January 2026 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Fulcrum Metals Plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2\. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights An acquisition or disposal of financial instruments An event changing the breakdown of voting rights X Other (please specify) iii: 3\. Details of person subject to the notification obligation iv Name Ryan Mee City and country of registered office (if applicable) 4\. Full name of shareholder(s) (if different from 3.) v Name City and country of registered office (if applicable) 5\. Date on which the threshold was crossed or reached vi: 23 January 2026 6\. Date on which issuer notified (DD/MM/YYYY): 30 January 2026 7\. Total positions of person(s) subject to the notification obligation % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii Resulting situation on the date on which threshold was crossed or reached 9.42% 13,024,123 Position of previous notification (if applicable) 10.46% 8\. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii A: Voting rights attached to shares Class/type of shares ISIN code (if possible) Number of voting rights ix % of voting rights Direct (DTR5.1) Indirect (DTR5.2.1) Direct (DTR5.1) Indirect (DTR5.2.1) GB00BPCPPZ79 13,024,123 9.42% SUBTOTAL 8. A B 1: Financial Instruments according to DTR5.3.1R (1) (a) Type of financial instrument Expiration date x Exercise/ Conversion Period xi Number of voting rights that may be acquired if the instrument is exercised/converted. % of voting rights SUBTOTAL 8. B 1 B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) Type of financial instrument Expiration date x Exercise/ Conversion Period xi Physical or cash Settlement xii Number of voting rights % of voting rights SUBTOTAL 8.B.2 9\. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii X Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold 10\. In case of proxy voting, please identify: Name of the proxy holder The number and % of voting rights held The date until which the voting rights will be held 11\. Additional information xvi Place of completion United Kingdom Date of completion 30 January 2026 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END HOLEAXFEDAKKEFA ### 相关股票 - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [Fulcrum Therapeutics (FULC.US)](https://longbridge.com/zh-CN/quote/FULC.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [Direxion S&P Biotech Bear 3X (LABD.US)](https://longbridge.com/zh-CN/quote/LABD.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) ## 相关资讯与研究 - [Longeveron Closes $15 Million Initial Tranche of $30 Million Private Placement](https://longbridge.com/zh-CN/news/278780841.md) - [bioAffinity Launches Major Lung Cancer Detection Study](https://longbridge.com/zh-CN/news/278565253.md) - [What is HC Wainwright's Estimate for KROS FY2030 Earnings?](https://longbridge.com/zh-CN/news/278112283.md) - [UCB reports superiority of bimekizumab in psoriatic arthritis study](https://longbridge.com/zh-CN/news/278691960.md) - [Capricor Theraputics Q4 revenue falls to zero, net loss widens](https://longbridge.com/zh-CN/news/278939139.md)